Review
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Sep 15, 2023; 15(9): 1505-1519
Published online Sep 15, 2023. doi: 10.4251/wjgo.v15.i9.1505
Table 1 Targeting various characteristics of pancreatic carcinomas and their associated therapeutic strategies
Potent therapeutics
Cancer Hallmarks
TGF-β pathway inhibitors HGF; Met pathway inhibitorsActivating invasion/metastasis
JAK/STAT pathway inhibitors; BTK inhibitors; Src inhibitors; COX-2 inhibitorsTumour-promoting inflammation
NRF2 pathway inhibitors; HIF-1 pathway inhibitors; PKCδ-PKD1 inhibitors; Amino acid transporter inhibitors; α-Glucosidase inhibitorsDeregulating cellular metabolism
EGF pathway inhibitors; Ras/Raf/ MEK/ERK pathway inhibitors; PI3K/AKT/mTOR pathway inhibitors; Wnt pathway inhibitors; PDGF pathway inhibitors; SCF/c-Kit pathway inhibitors; ALK pathway inhibitors; Hedgehog pathway inhibitorsSustaining proliferative signalling
IGF pathway inhibitors; NF-κB pathway inhibitorsResisting apoptosis
VEGF pathway inhibitorsInducing angiogenesis
Shh pathway inhibitors; FAK inhibitors; Src inhibitors; EGFR inhibitorsExpansive desmoplasia
Aurora kinase inhibitors; Cyclin-dependent kinase inhibitorsEluding growth suppressors
PD-L1 inhibitors; CTLA-4 inhibitorsAvoiding immune destruction
PARP inhibitors Photodynamic agents; Bromodomain inhibitors; HDAC inhibitorsGenome instability and damage